Patient self administration

The OTS system utilizes a lozenge-on-a-handle technology, where the dosage unit is administered by rotating and dissolving it against the oral mucosal tissue. The presence of a handle on the dosage form provides a convenient, simple mechanism for the patient to self-administer drugs to the oral cavity for either transmucosal or swallowed gastrointestinal absorption, depending on the drug application.

The OTS handle makes administration convenient and noninvasive, and allows patients to easily administer the drug. Simple, yet ingenious.

A convenient form for systemic delivery of drugs

The OTS product is manufactured by a direct compression process and is packaged in a convenient unit-dose blister package.


 

 

First prescription medication approved for the treatment of breakthrough pain in opioid-tolerant cancer patients

This technology has been commercialized with fentanyl citrate as the active drug under the brand name ACTIQ® (oral transmucosal fentanyl citrate, C-II). For important information for healthcare professionals and patients, and for Prescribing Information, including the boxed warning on ACTIQ, please visit www.actiq.com

Overview

Patient self administration

The OTS system utilizes a lozenge-on-a-handle technology, where the dosage unit is administered by rotating and dissolving it against the oral mucosal tissue. The presence of a handle on the dosage form provides a convenient, simple mechanism for the patient to self-administer drugs to the oral cavity for either transmucosal or swallowed gastrointestinal absorption, depending on the drug application.

The OTS handle makes administration convenient and noninvasive, and allows patients to easily administer the drug. Simple, yet ingenious.

Technical Notes

A convenient form for systemic delivery of drugs

The OTS product is manufactured by a direct compression process and is packaged in a convenient unit-dose blister package.


 

 

Case Study

First prescription medication approved for the treatment of breakthrough pain in opioid-tolerant cancer patients

This technology has been commercialized with fentanyl citrate as the active drug under the brand name ACTIQ® (oral transmucosal fentanyl citrate, C-II). For important information for healthcare professionals and patients, and for Prescribing Information, including the boxed warning on ACTIQ, please visit www.actiq.com